Table 1.
The correlation analysis between LINC00675 expression and clinicopathologic features of 74 BC patients
| Clinicopathological features | LINC00675 level |
P value | |
|---|---|---|---|
| Low (n = 37) | High (n = 37) | ||
| Age | 0.816 | ||
| ≤45 | 20 | 19 | |
| > 45 | 17 | 18 | |
| Subtype | 0.492 | ||
| ER+/PR+ | 28 | 27 | |
| HER2 positive | 6 | 4 | |
| TNBC | 3 | 6 | |
| Menopause | 0.480 | ||
| premenopause | 23 | 20 | |
| promenopause | 14 | 17 | |
| Tumor size | 0.352 | ||
| ≤ 2 cm | 17 | 21 | |
| > 2 cm | 20 | 16 | |
| Tumor grade | 0.002 | ||
| I–II | 17 | 30 | |
| III | 20 | 7 | |
| Lymphovascular invasion | 0.020 | ||
| Negative | 25 | 15 | |
| Positive | 12 | 22 | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
The median of LINC00675 in BC tissues was used as cutoff.